Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
With 56% Ownership, Accuray Incorporated (NASDAQ:ARAY) Boasts of Strong Institutional Backing
Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024
IMS Shin-Matsudo Central General Hospital Completes First Patient Treatment With the ZAP-X Gyroscopic Radiosurgery Platform
Accuray Incorporated (ARAY): The Best Robotics Stock Under $10?
Global Radiation Therapy Market With Focus on LINAC: Insights & Forecast 2024-2028, Featuring Profiles of Ion Beam Applications, Siemens Healthineers, Accuray, Elekta, ViewRay and Hitachi - ResearchAndMarkets.com
Dongguk University Ilsan Hospital Completes First Brain Tumor Treatments With the ZAP-X Gyroscopic Radiosurgery Platform
Loss-Making Accuray Incorporated (NASDAQ:ARAY) Expected To Breakeven In The Medium-Term
Express News | Long-term Customer Heidelberg University Hospital In Heidelberg, Germany, Has Selected Accuray's Radixact System, Equipped With ClearRT, Synchrony, And VOLO Ultra Optimizer Solutions, It Will Replace The Older Generation Accuray Tomotherapy System
Express News | Heidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care
Les Centres De Cancérologie Apollo Collaborent Avec Accuray Pour Lancer Le Premier Programme De Radiothérapie Stéréotaxique Robotisée Du Sous-continent Indien
Apollo Cancer Centres Collaborates With Accuray to Launch India Sub- Continent's First Robotic Stereotactic Radiotherapy Program
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
Express News | Accuray Announced An Agreement With TrueNorth Medical Physics To Provide Radiation Oncology Departments With Third-party Support Designed To Enhance Their Department's Capabilities
Express News | Accuray and Truenorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
Accuray's Precision Treatment Planning System Gains Approval in China
Lake Street Maintains Accuray(ARAY.US) With Buy Rating, Maintains Target Price $6
Accuray Precision TPS' Registration Dossier Approved in China
Express News | Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration
No Data